AcePre, LLC
Columbia, SC · Biotech · Private
Small-molecule therapeutic targeting pyruvate dehydrogenase kinase 1 (PDHK1) to modulate macrophage inflammasome activation and metabolic rewiring in sepsis
- Grants
- $3.0M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil | $261,212 | |
| Federal grant | Department of Health and Human Services · Phase I · Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil | $38,933 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Dietary Quercetin to Treat Muscle Wasting Disorders | $299,998 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel polymer-metal nanocomplex for ovarian cancer treatment | $392,803 | |
| Federal grant | Department of Health and Human Services · Phase I · Use novel natural compound Sparstolonin B to treat bacterial sepsis | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Dietary Quercetin to Treat Muscle Wasting Disorders | $52,000 | |
| Federal grant | Department of Health and Human Services · Phase I · The development of a multifunctional nanoenzyme for AD treatment | $299,628 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting macrophage maladaptation for bacterial sepsis treatment | $299,982 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting macrophage maladaptation for bacterial sepsis treatment | $297,328 | |
| Federal grant | Department of Health and Human Services · Phase I · Develop a novel strategy to deliver N-acetylcysteine for AD treatment | $499,441 | |
| Federal grant | Department of Health and Human Services · Phase I · Develop natural compound emodin as a novel therapy for calcific aortic valve disease | $299,953 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3204 | OM THERAPEUTICS INC. | — | — |
| 3205 | Anaveon | — | — |
| 3206 | IMETABOLIC BIOPHARMA CORPORATION | — | — |
| 3207 | AcePre, LLC | — | — |
| 3208 | CuronBiotech Inc | — | — |
| 3209 | Gerologix, Inc. | — | — |
| 3210 | Culture Robotics, Inc | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.